HIGHLIGHTS
- who: Wendy A. Lai from the University of Toronto Department of Family and Community Medicine, Toronto, Canada have published the article: Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review, in the Journal: (JOURNAL) of February/28,/2022
- what: Discussion and conclusion This is the first systematic review on the cost-effectiveness of 3HP compared to 9H for LTBI. Because missing a dose in a weekly regimen can lead to subtherapeutic drug levels, treatment failure, and development of drug resistance, the authors focus on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.